Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMMB NASDAQ:CVKD NASDAQ:DCOY NASDAQ:TRAW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$2.02$1.69$1.35▼$5.77$14.53M0.5145,881 shs90,067 shsCVKDCadrenal Therapeutics$5.19$5.50$4.21▼$15.99$14.89M1.8163,385 shs101,553 shsDCOYDecoy Therapeutics$7.30$6.16$4.32▼$415.80$3.88M0.3810,689 shs10,723 shsTRAWTraws Pharma$1.49$1.66$1.00▼$3.27$15.13M1.476.37 million shs787,532 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics0.00%+24.69%+25.47%+30.32%-63.00%CVKDCadrenal Therapeutics0.00%+7.68%-5.64%-33.38%-64.81%DCOYDecoy Therapeutics0.00%+56.99%+33.72%-14.08%+729,999,900.00%TRAWTraws Pharma0.00%-15.34%+28.45%-2.61%+13.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$2.02$1.69$1.35▼$5.77$14.53M0.5145,881 shs90,067 shsCVKDCadrenal Therapeutics$5.19$5.50$4.21▼$15.99$14.89M1.8163,385 shs101,553 shsDCOYDecoy Therapeutics$7.30$6.16$4.32▼$415.80$3.88M0.3810,689 shs10,723 shsTRAWTraws Pharma$1.49$1.66$1.00▼$3.27$15.13M1.476.37 million shs787,532 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics0.00%+24.69%+25.47%+30.32%-63.00%CVKDCadrenal Therapeutics0.00%+7.68%-5.64%-33.38%-64.81%DCOYDecoy Therapeutics0.00%+56.99%+33.72%-14.08%+729,999,900.00%TRAWTraws Pharma0.00%-15.34%+28.45%-2.61%+13.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics 2.00Hold$25.001,137.62% UpsideCVKDCadrenal Therapeutics 2.00Hold$13.00150.48% UpsideDCOYDecoy Therapeutics 2.00Hold$30.00310.96% UpsideTRAWTraws Pharma 2.50Moderate Buy$8.00436.91% UpsideCurrent Analyst Ratings BreakdownLatest DCOY, TRAW, CVKD, and CMMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026TRAWTraws Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/15/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/8/2026CMMBChemomab Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/7/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/1/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)4/22/2026DCOYDecoy Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/20/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/7/2026CVKDCadrenal Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$32.00 ➝ $13.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$1.49 per shareN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/A$0.63 per shareN/ADCOYDecoy TherapeuticsN/AN/AN/AN/A$7.29 per shareN/ATRAWTraws Pharma$2.79M5.43$0.76 per share1.95($0.52) per share-2.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$8.99M-$2.22N/AN/AN/AN/A-89.03%-79.68%8/13/2026 (Estimated)CVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%8/10/2026 (Estimated)DCOYDecoy Therapeutics-$12.52M-$106.90N/AN/AN/AN/A-395.42%-193.30%N/ATRAWTraws Pharma$9.17M-$1.69N/AN/AN/AN/A-913.18%-133.88%8/13/2026 (Estimated)Latest DCOY, TRAW, CVKD, and CMMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q4 2025TRAWTraws Pharma-$0.92-$0.53+$0.39-$0.53$2.72 millionN/A5/14/2026Q1 2026CMMBChemomab Therapeutics-$0.04-$0.22-$0.18$0.24N/AN/A5/8/2026Q1 2026DCOYDecoy TherapeuticsN/A-$4.18N/A-$4.18N/AN/A5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/A4/15/2026Q4 2025TRAWTraws Pharma-$1.2238-$0.71+$0.5138-$0.71$0.06 millionN/A3/31/2026Q4 2025CVKDCadrenal Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A3/31/2026Q4 2025DCOYDecoy TherapeuticsN/A$43.10N/A$43.10N/AN/A3/19/2026Q4 2025CMMBChemomab Therapeutics-$0.20-$0.24-$0.04-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ADCOYDecoy TherapeuticsN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A10.3110.31CVKDCadrenal TherapeuticsN/A2.682.68DCOYDecoy TherapeuticsN/A1.841.84TRAWTraws PharmaN/A0.430.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%CVKDCadrenal Therapeutics7.92%DCOYDecoy Therapeutics11.88%TRAWTraws Pharma7.95%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%CVKDCadrenal Therapeutics26.09%DCOYDecoy Therapeutics0.30%TRAWTraws Pharma14.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics207.19 million6.34 millionNot OptionableCVKDCadrenal Therapeutics42.87 million2.12 millionNot OptionableDCOYDecoy Therapeutics20530,000530,000N/ATRAWTraws Pharma1710.16 million8.74 millionNo DataDCOY, TRAW, CVKD, and CMMB HeadlinesRecent News About These CompaniesTraws Pharma (NASDAQ:TRAW) Receives Buy Rating from HC WainwrightMay 21, 2026 | americanbankingnews.comBioVie (NASDAQ:BIVI) vs. Traws Pharma (NASDAQ:TRAW) Financial ComparisonMay 20, 2026 | americanbankingnews.comTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsMay 15, 2026 | globenewswire.comTraws Pops on Hantavirus ResearchMay 9, 2026 | baystreet.caA hantavirus update has sent this nano-cap biotech stock surging today – here’s why retail sees potential 20x gainsMay 9, 2026 | msn.comTraws Pharma Gains After Hantavirus Drug Development Update Amid Cruise Ship OutbreakMay 8, 2026 | benzinga.comTraws Pharma Advances Development of Clinical Candidates for Hantavirus TreatmentMay 8, 2026 | quiverquant.comQTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsMay 8, 2026 | globenewswire.comTraws Pharma (TRAW) price target decreased by 24.14% to 5.61April 29, 2026 | msn.comTraws Pharma (NASDAQ:TRAW) Major Shareholder Purchases $998,207.43 in StockApril 29, 2026 | insidertrades.comNewtown-based Traws Pharma shares full-year results, clinical progressApril 23, 2026 | msn.comTraws Pharma Takes Flight: Revolutionary Flu Prophylactic Poised to SoarApril 21, 2026 | news.themarketisopen.comNTraws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?April 20, 2026 | zacks.comTraws Pharma, Inc. Q4 2025 Earnings Call SummaryApril 16, 2026 | finance.yahoo.comTraws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...April 16, 2026 | finance.yahoo.comTraws outlines $60M financing while targeting flu challenge study this summer and runway into Q1 2027April 16, 2026 | seekingalpha.comTraws Pharma Announces Up to $60 Million Private Placement FinancingApril 16, 2026 | markets.businessinsider.comTraws Pharma, Inc. (TRAW) Q4 2025 Earnings Call TranscriptApril 16, 2026 | seekingalpha.comTraws Pharma Reports Full Year 2025 Results and Provides Business HighlightsApril 15, 2026 | globenewswire.comTraws Pharma Secures $10 Million PIPE Financing to Advance Influenza Program in Human Challenge TrialApril 15, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCOY, TRAW, CVKD, and CMMB Company DescriptionsChemomab Therapeutics NASDAQ:CMMB$2.02 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.06 +0.04 (+1.93%) As of 05/22/2026 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Cadrenal Therapeutics NASDAQ:CVKD$5.19 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$5.05 -0.14 (-2.77%) As of 05/22/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Decoy Therapeutics NASDAQ:DCOY$7.30 0.00 (0.00%) Closing price 05/22/2026 03:54 PM EasternExtended Trading$7.70 +0.40 (+5.47%) As of 05/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Traws Pharma NASDAQ:TRAW$1.49 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.50 +0.01 (+0.60%) As of 05/22/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
